Reading the graph
Private equityDeal
AVS Bio and Biorbyt: the announcement, its sources and the records DFX holds on each party.
AVS Bio announced the transaction on September 23, 2026.
Check this story against the records it counts, in the Data Factory screen filtered the same way.
Private equity transactions announced since Mar 24, 2026The first rows are open to every reader; the full list, exports and alerts come with a DFX plan. See what a plan includes
The merger filing shows how the deal is paid for: $2.87 billion of equity from CD&R and McKesson and up to $3.15 billion of committed bank loans, against about $5.95 billion of uses.
Gen II says it serves more than 275 managers with over $2 trillion in assets. In the $48.1 billion slice DFX can tie to it in SEC fund filings, Stonepeak's funds hold about 43%, and the clients lean to institutional managers.